The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
UKONS 2018 | Key scientific principles for nurses managing patients on CAR T-cell therapy
Key scientific principles that hematology nurses need to be aware of to manage patients receiving CAR T-cell therapy are discussed here by Kathleen McDermott, RN, BSN, OCN, BMTCN, of the Dana-Farber Cancer Institute, Boston, MA. She highlights the need for nurse education on various aspects of CAR T-cell therapy, such as toxicity knowledge and management, CRP measurement, and awareness of toxicity grading. This interview took place at the UK Oncology Nursing Society (UKONS) 2018 Annual Conference, in Glasgow, UK.
